tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Piper starts Janux Therapeutics with an Overweight on ‘best-in-class’ potential

As previously reported, Piper Sandler initiated coverage of Janux Therapeutics (JANX) with an Overweight rating and $42 price target While noting that investor sentiment has waned over the course of 2025 following the announcement of completion of the JANX007 dose escalation and emergence of competitor clinical data, it continues to think JANX007 is “a differentiated, potentially best-in-class program” in metastatic castration-resistant prostate cancer. The firm views the recent stock pullback offering “an attractive entry point” ahead of clinical updates due later this year, the analyst added.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1